Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
:PTN
PTN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $2.88
Previous CloseN/A
Volume114.38K
Average Volume (3M)682.13K
Market Cap
$17.22M
Enterprise ValueN/A
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)$357.74K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 20, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding26,005,846
10 Day Avg. Volume965,907
30 Day Avg. Volume682,133
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)60.14
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside960.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Palatin Technologies News
PremiumCompany Announcements
Palatin Technologies Reports Q2 2025 Financial Results
PremiumCompany Announcements
Palatin’s Earnings Call: Mixed Results and Strategic Moves
---
Bulls Say, Bears Say
Bulls Say
Market ValuationThe valuation of Palatin's stock appears attractive based on the initial addressable market size, supporting the Buy rating and price target.
Obesity Program SuccessThe completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.
Strategic ShiftPalatin's strategic focus has shifted primarily to its obesity program, which management views as the primary driver of long-term success.
Bears Say
Clinical Trial UncertaintyPalatin may need to achieve more than 7-8% weight loss from baseline with a comparable or better safety profile using its combination approach to achieve positive investor sentiment.
Funding ChallengesFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.
---
Ownership Overview
2.92% Insiders
2.92% Mutual Funds
8.17% Other Institutional Investors
83.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $0.62 and its highest was $2.88 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Palatin Technologies Inc’s market cap is $17.22M.
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is May 20, 2025 which is in 50 days.
How were Palatin Technologies Inc’s earnings last quarter?
Palatin Technologies Inc released its earnings results on Feb 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.3.
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -0.17.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 26,005,846 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Palatin Technologies Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went up 7.071%.
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Currently, no hedge funds are holding shares in PTN
---
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
---
PTN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with significant achievements in reducing net loss and promising clinical trial results. However, challenges remain with the absence of product sales and a decrease in cash position. The company is actively pursuing strategic partnerships to enhance its future prospects.Read More>---
PTN Stock 12 Month Forecast
Average Price Target
$7.00
▲(960.61% Upside)
Technical Analysis
Best Analysts Covering PTN
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-37.51%
reiterated a buy rating 11 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -37.51% per trade.
---